| 1.55 0.43 (38.39%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.99  |
1-year : | 4.13 |
| Resists | First : | 2.56 |
Second : | 3.53 |
| Pivot price | 1.14 |
|||
| Supports | First : | 0.99 | Second : | 0.82 |
| MAs | MA(5) : | 1.2 |
MA(20) : | 1.14 |
| MA(100) : | 3.01 |
MA(250) : | 3 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 53.4 |
D(3) : | 47.1 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 5.07 | Low : | 0.99 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LSTA ] has closed Bollinger Bands are 58.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.79 - 1.79 | 1.79 - 1.8 |
| Low: | 1.09 - 1.1 | 1.1 - 1.1 |
| Close: | 1.54 - 1.55 | 1.55 - 1.56 |
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Fri, 21 Aug 2026
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Wed, 05 Aug 2026
Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment - The Globe and Mail
Tue, 04 Aug 2026
Lisata Therapeutics Files Suit Against Kuva Labs, Reviews Strategic Alternatives and Cuts Workforce to Preserve Cash - Quiver Quantitative
Tue, 04 Aug 2026
Lisata Therapeutics moves forward with legal action following Kuva merger termination - Yahoo! Finance Canada
Tue, 04 Aug 2026
Lisata Therapeutics Provides Update Following Termination of Merger Agreement - Stock Titan
Tue, 28 Jul 2026
Kuva Labs (LSTA) ends Lisata cash-and-CVR tender offer after financing shortfall - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 7.2e+006 (%) |
| Held by Institutions | 20.8 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.72e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 178.8 % |
| Return on Equity (ttm) | -50.3 % |
| Qtrly Rev. Growth | 170000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -103.88 |
| EBITDA (p.s.) | 193182 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 118.4 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 1.13 |
| Dividend | 0 |
| Forward Dividend | 129920 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|